Chagas Cardiomyopathy
16
2
2
10
Key Insights
Highlights
Success Rate
91% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
6.3%
1 terminated out of 16 trials
90.9%
+4.4% vs benchmark
38%
6 trials in Phase 3/4
0%
0 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (16)
Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease
Cardiac Contractility Modulation in Chagas Heart Disease
Cardiac Mechanics by Speckle Tracking as a Prognostic Predictor in Patients With Chagas Cardiomyopathy
Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death
Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease.
Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children
Physical Exercise Program in Chronic Chagas Heart Disease
A Trial Testing Amiodarone in Chagas Cardiomiopathy
Cell Therapy in Chagas Cardiomyopathy
Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy
A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
Cardiac Rehabilitation in Chagas Heart Failure
Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort
Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity